Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.
Let's turn to Teva Pharmaceutical . The drug company has a unique balance, profiting from generics on one hand yet having its own proprietary drugs on the other. Let's take an early look at what's been happening with Teva Pharmaceutical over the past quarter and what we're likely to see in its quarterly report on Thursday.
Stats on Teva Pharmaceutical
Analyst EPS Estimate
Change from Year-Ago EPS
Change from Year-Ago Revenue
Earnings Beats in Past 4 Quarters
Source: Yahoo! Finance.
Will Teva Pharmaceutical stay healthy?
Analysts have been pretty certain about their estimates for Teva Pharmaceutical in the just-concluded quarter, but over the past three months, they've pulled in their estimates for the first quarter and full-year 2013 sharply. The stock has been equally pessimistic, falling almost 8% since early November.
Teva is best known for its generic versions of off-patent drugs. Given how much less expensive generic versions are compared to their branded equivalents, health-care advocates argue that they're essential to keeping drug costs down, even though they also discourage innovation. Teva hasn't been content to stick with generics solely, though, also working on branded drugs. Its blockbuster drug is Copaxone, which is a treatment for multiple sclerosis.
For Copaxone, though, competition is on the horizon. Teva filed what's known as a citizen's petition with the FDA to try to delay approval of Biogen Idec's BG-12 treatment for MS, which will go up directly against Copaxone if approved.
Meanwhile, Teva is looking to for future growth from biosimilars, which currently represents an untapped market. Biologic drugs have been a promising area for branded-drug makers, and Teva is a player in that field, with its Tbo-filgrastim set to launch late this year to go up against Amgen's Neupogen. But if biosimilars -- essentially generic versions of biologics -- work as well as generic drugs have, then Teva could pioneer a whole new profit center.
In Teva's quarterly report, investors need to watch how the company plans to address the trend toward branded-drug makers marketing their own post-patent generic versions to retain sales. Pfizer did that extremely well when Lipitor went off-patent, and if others follow suit, Teva needs a better plan than just cost savings to come out the competitive winner in the space.
Find the best stocks
Regardless of whether you like drug stocks, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Click here to add Teva Pharmaceutical to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
The article Teva Pharmaceutical Earnings: An Early Look originally appeared on Fool.com.
Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.